Pelthos Therapeutics (NYSEAMERICAN:PTHS) Cut to “Strong Sell” at Zacks Research

Posted by Brian Himes on Oct 9th, 2026

Pelthos Therapeutics (NYSEAMERICAN:PTHS – Get Free Report) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Wednesday, Zacks reports.

Separately, Oppenheimer reduced their price objective on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating on the stock in a report on Friday, August 14th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Pelthos Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $55.40.

Read Our Latest Stock Report on Pelthos Therapeutics

Pelthos Therapeutics Trading Down 2.3%

Shares of Pelthos Therapeutics stock opened at $20.50 on Wednesday. The firm has a market capitalization of $78.52 million, a price-to-earnings ratio of -0.94 and a beta of 3.07. Pelthos Therapeutics has a fifty-two week low of $18.19 and a fifty-two week high of $37.50. The company has a debt-to-equity ratio of 3.40, a quick ratio of 1.31 and a current ratio of 1.98. The stock has a 50 day moving average of $24.40 and a 200 day moving average of $25.18.

Pelthos Therapeutics (NYSEAMERICAN:PTHS – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($6.62) EPS for the quarter. Pelthos Therapeutics had a negative net margin of 165.24% and a negative return on equity of 204.71%. The business had revenue of $15.60 million during the quarter. As a group, research analysts predict that Pelthos Therapeutics will post -15.22 earnings per share for the current year.

Institutional Investors Weigh In On Pelthos Therapeutics

A hedge fund recently raised its position in Pelthos Therapeutics stock. Knott David M Jr boosted its position in shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS – Free Report) by 9.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,073 shares of the company’s stock after acquiring an additional 1,792 shares during the quarter. Knott David M Jr owned 0.63% of Pelthos Therapeutics worth $443,000 at the end of the most recent quarter. 77.96% of the stock is currently owned by institutional investors.

Pelthos Therapeutics Company Profile

(Get Free Report)

Pelthos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for pain management. The company’s work is centered on addressing unmet needs in the treatment of acute and chronic pain, including the development of potential alternatives to traditional opioid-based medicines.

Pelthos Therapeutics is advancing investigational drug candidates through preclinical and clinical development. As with other clinical-stage biotechnology companies, its products remain subject to testing and regulatory review, and there is no assurance that any candidate will receive approval or become commercially available.

Publicly available information about the company’s specific product pipeline, operating history, geographic reach and leadership is limited.